Evidence map›Paper›PMID 39680192›Full record

ArticleLangenbeck's archives of surgery2024

Curative treatment for oligometastatic gastroesophageal cancer- results of a prospective multicenter study.

N Norén, I Rouvelas, L Lundell, M Nilsson, B Sunde, E Szabo, D Edholm, J Hedberg, U Smedh, M Hermansson and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

N NorénDepartment of Surgery and Oncology, CLINTEC, Karolinska Institutet, Dep. of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, Sweden. nora.noren@ki.se.
I RouvelasDepartment of Surgery and Oncology, CLINTEC, Karolinska Institutet, Dep. of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, Sweden.
L LundellDepartment of Surgery and Oncology, CLINTEC, Karolinska Institutet, Dep. of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, Sweden.
M NilssonDepartment of Surgery and Oncology, CLINTEC, Karolinska Institutet, Dep. of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, Sweden.
B SundeDepartment of Surgery and Oncology, CLINTEC, Karolinska Institutet, Dep. of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, Sweden.
E SzaboÖrebro University Hospital, Örebro, Sweden.
D EdholmDepartment of Surgery, Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
J HedbergDepartment of Surgical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden.
U SmedhSahlgrenska University Hospital, Gothenburg, Sweden.
M HermanssonDepartment of Surgery, Skåne University Hospital and Department of Clinical Sciences, Lund University, Lund, Sweden.
M LindbladDepartment of Surgery and Oncology, CLINTEC, Karolinska Institutet, Dep. of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, Sweden.
F KlevebroDepartment of Surgery and Oncology, CLINTEC, Karolinska Institutet, Dep. of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOligometastatic gastroesophageal cancer is a clinical entity with no standard treatment recommendation. Treatment with curative intent has recently emerged as an option for selected patients in contrast to the traditional palliative treatment strategy. This prospective study aimed to assess the safety and efficacy of combined systemic and local treatment with curative intent for patients with oligometastatic gastroesophageal cancer.

methodsIn a multicenter study, consecutive patients with gastroesophageal cancer and metastases in the liver and/or extra-regional lymph nodes were screened for inclusion. Eligible patients were offered curatively intended perioperative chemotherapy followed by surgical resection or liver ablation. Primary endpoints were treatment safety and feasibility. Secondary outcomes included postoperative mortality, treatment response, progression-free survival, and overall survival. Subgroup analyses were stratified based on oligometastatic location.

resultsA total of 29 (82.9%) patients completed treatment with surgical resection (93.1%), liver ablation (3.4%), or definitive chemoradiotherapy (3.4%). Postoperative complications were found in 19 (73.1%) patients, whereas postoperative mortality was 0%. The most common complications included infection (34.6%) and respiratory complications (34.6%). Median overall survival was 20.9 months (interquartile range 11.2-42.6) from diagnosis and 17.0 months (interquartile range 6.4-35.9) from surgery in patients who were treated with neoadjuvant chemotherapy followed by surgery. Median progression-free survival was 5.8 months (interquartile range 3.1-11.3).

conclusionThis study found curative treatment to be a relatively safe option, with an overall survival of 20.8 months and no postoperative mortality.

Indexed as

Esophageal NeoplasmsStomach NeoplasmsAgedCombined Modality TherapyFemaleHumansLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedProspective StudiesSurvival RateTreatment OutcomeEsophageal cancerGastric cancerOligometastatic gastroesophageal cancerOverall survivalPostoperative complications

Identifiers

PMID39680192
PMCPMC11649779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.